PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPhysiomics Regulatory News (PYC)

Share Price Information for Physiomics (PYC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.25
Bid: 1.10
Ask: 1.40
Change: 0.00 (0.00%)
Spread: 0.30 (27.273%)
Open: 1.25
High: 1.25
Low: 1.25
Prev. Close: 1.25
PYC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Recent Price Movements and Press Speculation

14 May 2010 12:08

RNS Number : 9497L
Physiomics PLC
14 May 2010
 



 

 

Physiomics plc

("Physiomics" or "the Company")

Recent Price Movements and Press Speculation

 

The directors of Physiomics note the recent price movements and press speculation.

 

The directors can confirm that the only corporate deal of significance at present is with an Indian Contract Research Organisation (the "ICRO"). It is intended that, if negotiations are successful, Physiomics and the ICRO will execute an agreement pursuant to which Physiomics will develop a predictive cancer model in association with ICRO. It is not anticipated that any revenue will be generated from the first stage of this deal but it may be that, if the first stage is successful, a further revenue generating commercial arrangement will be executed in the future between the parties.

 

A further announcement will be made in due course, if an agreement is executed.

 

Enquiries:

 

Physiomics plc

Dr Christophe Chassagnole, COO 

+44 (0)1865 784980

 

WH Ireland Limited

Katy Mitchell

+44 (0) 161 832 2174

 

 

About Physiomics plc

Physiomics plc (AIM:PYC) is a computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials. As 80-90 per cent of all clinical drug candidates fail to reach the market, estimates1 show that an overall ten per cent improvement in success rates could reduce the cost of one drug's development by as much as $242 million, from the current estimate of around $800 million.

Physiomics develops computational systems biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. Physiomics has created detailed mathematical models incorporating most important molecular events taking place during the human cell cycle and apoptosis processes. Physiomics developed SystemCell® technology, a multi-cellular environment software, which enables the simulation of population of "virtual cells".

Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in 2004. For further information, please visit www.physiomics-plc.com

 

SystemCell® is a registered trademark of Physiomics plc

1Tufts Centre Impact Report 2002

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
SPMGGUAUAUPUGGC
Date   Source Headline
31st Mar 20067:00 amPRNInterim Results
22nd Dec 20051:04 pmPRNAGM Statement
25th Oct 20053:02 pmPRNStatement re: Partial Investing of Share Options
18th Oct 200512:06 pmPRNDirector/PDMR Shareholding
8th Sep 20056:00 amPRNFinal Results
26th Aug 20056:00 amPRNDirectorate Change
28th Jun 200510:48 amPRNAdditional Listing
27th Jun 20056:00 amPRNStatement re share subscription and issue of options
23rd Jun 20056:00 amPRNRe Agreement
21st Mar 20057:00 amPRNInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.